Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor.

Leilani L. Santos(Royal Women's Hospital), Eric F. Morand(Novartis (Switzerland)), Derek Lacey(Monash Medical Centre), Michelle Leech(Monash Institute of Medical Research), Yuanhang Yang
PubMed
June 1, 2004
Cited by 60

Related Papers

Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570